WeVote
Log In

Bill

DG

Bill

A 2001

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

2026-2027 Regular Session Introduced by Don Guardian and 2 co-sponsors

NJ would exempt certain FDA-approved dialysate drugs/devices for home dialysis from standard pharmacist licensure, with strict FDA, distributor, physician-order, and weekly QA over

Reported out of Assembly Committee, 2nd Reading
0
WeVote Research Nonpartisan
Bill Summary · A 2001

Summary of New Jersey Bill A-2001 (Session 222)

Bill at a Glance

  • Jurisdiction: New Jersey
  • Title: Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices
  • Sponsor(s): Co-sponsors Gerry Scharfenberger and Annette Quijano
  • Status: Introduced 2026; reported and referred to Assembly Oversight, Reform and Federal Relations Committee (Feb 12, 2026); introduced earlier (Jan 13, 2026) and referred to Assembly Regulated Professions Committee
  • Effective Date: The act would take effect on the first day of the third month after enactment.

1) Main Purpose and Intent

The bill amends P.L.2003, c.280 to create a limited exemption from general pharmacist licensing requirements for the distribution of certain dialysis-related drugs and devices used for home dialysis in patients with end-stage renal disease (ESRD). The intent appears to facilitate the distribution of dialysate drugs and devices directly from manufacturers or wholesale distributors to patients or health care providers for home dialysis, while maintaining safety and regulatory oversight.

2) Key Provisions and Changes

  • Pharmacist Licensing Framework (General Practice):

    • Section 10 of P.L.2003, c.280 is amended to reaffirm that practice of pharmacy generally requires licensure, with exemptions for certain activities consistent with the existing statute.
    • The act clarifies that the standard licensing requirements do not apply to specific dialysate drugs or devices distribution under the exemption, subject to strict criteria.

  • Exemption for Dialysate Drugs/Devices (Home Dialysis):

    • The exemption applies to dialysate drugs or devices necessary to perform home dialysis for ESRD patients.
    • Conditions for the exemption include:
    • The products must be FDA-approved.
    • The products must be held by a properly registered manufacturer or wholesale drug distributor.
    • Products must be in original, sealed, labeled packaging from the manufacturing facility.
    • Delivery must be performed only by the manufacturer or its agent, and only upon a physician’s order.
    • Delivery destinations:
      • Directly to an ESRD patient or the patient’s designee for self-administration, or
      • To a health care provider or institution for administration/delivery of dialysis therapy to an ESRD patient.
    • The manufacturer must contract with a consultant pharmacist (properly registered by the board) to provide weekly quality assurance assessments of home dialysis drug storage and distribution.

  • Oversight and Quality Assurance:

    • A consultant pharmacist (board-registered) must be contracted to perform weekly quality assurance checks on storage and distribution for home dialysis medications.

  • Scope and Limits:

    • The exemption is narrowly tailored to dialysate drugs and devices used for home dialysis and relies on adherence to FDA approvals and regulatory registrations.
    • It complements, rather than replaces, existing pharmacy licensing and professional standards, requiring coordination with physician orders and institutional settings where applicable.

3) Who/What Would Be Affected

  • Manufacturers and Wholesale Drug Distributors:
    • Could distribute specified dialysate drugs/devices outside traditional pharmacist licensure regimes, provided all criteria are met.
  • Physicians and Health Care Providers:
    • Remain responsible for prescribing and ordering dialysate products for home dialysis; orders trigger delivery by manufacturers/agents.
  • End-Stage Renal Disease Patients (Home Dialysis):
    • Potentially have improved access to necessary dialysate drugs/devices delivered for home use upon physician orders.
  • Board-Registered Consultant Pharmacists:
    • Must be contracted by manufacturers to conduct weekly QA assessments of home dialysis drug storage and distribution.
  • Pharmacists and Licensed Pharmacies:
    • Retain general licensure requirements for traditional pharmacy activities; subject to the exemption only when the specific conditions are satisfied.

4) Procedural and Timeline Considerations

  • Effective Date: Start on the first day of the third month after enactment.
  • Regulatory Compliance: Requires FDA approval status, proper registration of manufacturers/distributors, secure packaging, physician orders, direct-to-patient or facility delivery, and weekly QA oversight by a consultant pharmacist.
  • Implementation Oversight: The bill adds a QA mechanism (weekly consultant pharmacist review) to ensure ongoing safety and compliance in home-dialysis drug storage and distribution.

Notes

  • The bill is focused on balancing patient access to essential home-dialysis products with regulatory safeguards, ensuring product integrity, proper administration, and ongoing quality oversight.
  • As with all regulatory exemptions, full implementation would depend on consistency with federal law, FDA approvals, and NJ board regulations for pharmacists and consultants.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.